Company Analysis Kinnate Biopharma Inc.
1. Summary
Advantages
- Price (2.65 $) is less than fair price (3.57 $)
- The stock's return over the last year (10.42%) is higher than the sector average (-12.5%).
Disadvantages
- Dividends (0%) are below the sector average (0.541%).
- Current debt level 1.83% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-70.7%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Kinnate Biopharma Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 2.5% | -0.7% |
| 90 days | 0% | -17.8% | 2.6% |
| 1 year | 10.4% | -12.5% | 25.7% |
KNTE vs Sector: Kinnate Biopharma Inc. has outperformed the "Healthcare" sector by 22.92% over the past year.
KNTE vs Market: Kinnate Biopharma Inc. has significantly underperformed the market by -15.24% over the past year.
Stable price: KNTE is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: KNTE with weekly volatility of 0.2003% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (2.65 $) is lower than the fair price (3.57 $).
Price significantly below the fair price: The current price (2.65 $) is 34.7% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.7162) is lower than that of the sector as a whole (4.83).
P/BV vs Market: The company's P/BV (0.7162) is lower than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (33.77).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.51) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.51) is lower than that of the market as a whole (28.32).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 42.58% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (42.58%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (4135.44%).
5.4. ROE
ROE vs Sector: The company's ROE (-70.7%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-70.7%) is lower than that of the market as a whole (10.71%).
5.5. ROA
ROA vs Sector: The company's ROA (-64.89%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-64.89%) is lower than that of the market as a whole (6.47%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-29.03%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-29.03%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.541%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
